Gregory A. Broderick

Gregory A. Broderick

Auto-generated profile, based on publicly available information

Gregory A. Broderick

Department of Urology, Mayo Clinic, Jacksonville, FL, USA

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 1998 in JAMA
Verified
Journal Article
Open access
PDF file
ADAnthony V. D'AMico
Anthony V. D'AMico
RWRichard Whittington
Richard Whittington
SMS. Bruce Malkowicz
S. Bruce Malkowicz
DSDelray Schultz
Delray Schultz
KBKenneth Blank
Kenneth Blank
AWAlan Wein
Alan Wein
Research from JAMA — Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer — Context.—Interstitial radiation (implant) therapy is used to treat clinically localized adenocarcinoma of the prostate, but how it compares with other treatments is not known.Objective.—To estimate control of prostate-specific antigen (PSA) after radical prostatectomy (RP), external beam radiation (RT), or implant with or without neoadjuvant androgen deprivation therapy in patients with clinically localized prostate cancer.Design.—Retrospective cohort study of outcome data compared using Cox regression multivariable analyses.Setting and Patients.—A total of 1872 men treated between January 1989 and October 1997 with an RP (n=888) or implant with or without neoadjuvant androgen deprivation therapy (n=218) at the Hospital of the University of Pennsylvania, Philadelphia, or RT (n=766) at the Joint Center for Radiation Therapy, Boston, Mass, were enrolled.Main Outcome Measure.—Actuarial freedom from PSA failure (defined as PSA outcome).Results.—The relative risk (RR) of PSA failure in low-risk patients (stage T1c, T2a and PSA level ≤10 ng/mL and Gleason score ≤6) treated using RT, implant plus androgen deprivation therapy, or implant therapy was 1.1 (95% confidence interval [CI], 0.5-2.7), 0.5 (95% CI, 0.1-1.9), and 1.1 (95% CI, 0.3-3.6), respectively, compared with those patients treated with RP. The RRs of PSA failure in the intermediate-risk patients (stage T2b or Gleason score of 7 or PSA level >10 and ≤20 ng/mL) and high-risk patients (stage T2c or PSA level >20 ng/mL or Gleason score ≥8) treated with implant compared with RP were 3.1 (95% CI, 1.5-6.1) and 3.0 (95% CI, 1.8-5.0), respectively. The addition of androgen deprivation to implant therapy did not improve PSA outcome in high-risk patients but resulted in a PSA outcome that was not statistically different compared with the results obtained using RP or RT in intermediate-risk patients. These results were unchanged when patients were stratified using the traditional rankings of biopsy Gleason scores of 2 through 4 vs 5 through 6 vs 7 vs 8 through 10.Conclusions.—Low-risk patients had estimates of 5-year PSA outcome after treatment with RP, RT, or implant with or without neoadjuvant androgen deprivation that were not statistically different, whereas intermediate- and high-risk patients treated with RP or RT did better then those treated by implant. Prospective randomized trials are needed to verify these findings.

1 October 2003 in Journal of Urology
Verified
Journal Article
Closed access
PDF file
DMDrogo K. Montague
Drogo K. Montague
JJJonathan Jarow
Jonathan Jarow
GBGregory A. Broderick
Gregory A. Broderick
RDRoger R. Dmochowski
Roger R. Dmochowski
JHJeremy P.W. Heaton
Jeremy P.W. Heaton
MPMembers Of The Erectile Dysfunction Guideline Update Panel
Members Of The Erectile Dysfunction Guideline Update Panel

1 July 2008 in The Journal of Sexual Medicine
Verified
Journal Article
Closed access
PDF file
CMChris G. McMahon
Chris G. McMahon
SAStanley E. Althof
Stanley E. Althof
MWMarcel D. Waldinger
Marcel D. Waldinger
HPHartmut Porst
Hartmut Porst
JDJohn Dean
John Dean
RSRobert Segraves
Robert Segraves

1 January 2010 in The Journal of Sexual Medicine
Verified
Journal Article
Closed access
PDF file
GBGregory A. Broderick
Gregory A. Broderick
AKAtes Kadioglu
Ates Kadioglu
TBTrinity J. Bivalacqua
Trinity J. Bivalacqua
HGHussein Ghanem
Hussein Ghanem
ANAjay Nehra
Ajay Nehra
RSRany Shamloul
Rany Shamloul

1 November 2010 in The Journal of Sexual Medicine
Verified
Journal Article
Closed access
PDF file
FMFrancesco Montorsi
Francesco Montorsi
GAGanesan Adaikan
Ganesan Adaikan
EBEdgardo Becher
Edgardo Becher
FGFrancois Giuliano
Francois Giuliano
SKSaad Khoury
Saad Khoury
MWMarlene Wasserman
Marlene Wasserman

1 September 2010 in The Journal of Sexual Medicine
Verified
Journal Article
Closed access
PDF file
SAStanley E. Althof
Stanley E. Althof
CACarmita H.N. Abdo
Carmita H.N. Abdo
JDJohn Dean
John Dean
GHGeoff Hackett
Geoff Hackett
MMMarita McCabe
Marita McCabe
HTHui Meng Tan
Hui Meng Tan